Bonacasa B, Sanchez M L, Rodriguez F, Lopez B, Quesada T, Fenoy F J, Hernández I
Department of Physiology, Facultad de Medicina, Universidad de Murcia, Spain.
Maturitas. 2008 Dec 20;61(4):310-6. doi: 10.1016/j.maturitas.2008.09.028. Epub 2008 Nov 17.
Accumulating data provide evidence that some metabolites of 17beta-estradiol are biologically active and mediate multiple effects on the cardiovascular and renal systems. We investigated the effect of 2-methoxyestradiol (an active metabolite of estradiol with non-feminizing activity) on the development of hypertension and myocardial vascular remodeling in male and female ovarectomized SHR.
Rats were divided into five groups: intact females, ovarectomized (OVX), OVX+ 2-methoxyestradiol (2ME), control males, and male+2ME. Systolic blood pressure was determined from 10 to 18 weeks. Structural changes in coronary vessels were quantified by an image analyzer. Immunoblotting of phosphorylated ERK1/2 and NADPH oxidase activity were performed on mesenteric arteries.
Treatment with 2ME reduced the increase in systolic blood pressure in male and ovarectomized rats to values not different from those obtained in intact females. Myocardial arterioles and small arteries showed significant increases in wall-to-lumen ratio and perivascular fibrosis in male and ovarectomized rats when compared with intact females. NADPH oxidase activity was increased in mesenteric arteries from males and ovarectomized females as compared with intact females. Finally, the expression of phosphorilated ERK1/2 were significantly higher in mesenteric arteries from male and ovariectomized animals than in those from intact females. Those effects of ovarectomy and gender differences were totally or partially prevented by treatment with 2-methoxyestradiol.
These data demonstrate that 2-methoxyestradiol protects the vasculature from hypertension-induced myocardial arterial remodeling in male and ovarectomized SHR, and that might be in part related to decreased superoxide generation and ERK1/2 activation.
越来越多的数据表明,17β-雌二醇的某些代谢产物具有生物活性,并介导对心血管和肾脏系统的多种作用。我们研究了2-甲氧基雌二醇(一种具有非女性化活性的雌二醇活性代谢产物)对雄性和雌性去卵巢自发性高血压大鼠(SHR)高血压发展和心肌血管重塑的影响。
将大鼠分为五组:未切除卵巢的雌性大鼠、去卵巢(OVX)大鼠、OVX + 2-甲氧基雌二醇(2ME)大鼠、对照雄性大鼠和雄性 + 2ME大鼠。在10至18周期间测定收缩压。通过图像分析仪对冠状动脉的结构变化进行定量分析。对肠系膜动脉进行磷酸化ERK1/2的免疫印迹分析和NADPH氧化酶活性检测。
用2ME治疗可将雄性和去卵巢大鼠收缩压的升高幅度降低至与未切除卵巢的雌性大鼠相当的水平。与未切除卵巢的雌性大鼠相比,雄性和去卵巢大鼠的心肌小动脉和小动脉的壁腔比及血管周围纤维化显著增加。与未切除卵巢的雌性大鼠相比,雄性和去卵巢雌性大鼠肠系膜动脉中的NADPH氧化酶活性增加。最后,雄性和去卵巢动物的肠系膜动脉中磷酸化ERK1/2的表达明显高于未切除卵巢的雌性大鼠。卵巢切除和性别差异所产生的这些影响可通过2-甲氧基雌二醇治疗得到完全或部分预防。
这些数据表明,2-甲氧基雌二醇可保护血管免受雄性和去卵巢SHR中高血压诱导的心肌动脉重塑,这可能部分与超氧化物生成减少和ERK1/2激活降低有关。